Liquidia Corp (LQDA)
13.07
-0.10
(-0.76%)
USD |
NASDAQ |
May 02, 13:16
Liquidia Research and Development Expense (Quarterly): 12.83M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 12.83M |
| September 30, 2023 | 7.44M |
| June 30, 2023 | 17.70M |
| March 31, 2023 | 5.278M |
| December 31, 2022 | 4.976M |
| September 30, 2022 | 4.512M |
| June 30, 2022 | 5.219M |
| March 31, 2022 | 4.728M |
| December 31, 2021 | 5.381M |
| September 30, 2021 | 4.487M |
| June 30, 2021 | 4.595M |
| March 31, 2021 | 6.054M |
| December 31, 2020 | 5.248M |
| September 30, 2020 | 7.661M |
| Date | Value |
|---|---|
| June 30, 2020 | 8.490M |
| March 31, 2020 | 10.82M |
| December 31, 2019 | 8.161M |
| September 30, 2019 | 10.94M |
| June 30, 2019 | 10.72M |
| March 31, 2019 | 10.66M |
| December 31, 2018 | 7.999M |
| September 30, 2018 | 7.157M |
| June 30, 2018 | 5.918M |
| March 31, 2018 | 7.627M |
| December 31, 2017 | 6.788M |
| September 30, 2017 | 6.533M |
| June 30, 2017 | 5.258M |
| March 31, 2017 | 6.176M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
4.487M
Minimum
Sep 2021
17.70M
Maximum
Jun 2023
7.644M
Average
6.054M
Median
Mar 2021
Research and Development Expense (Quarterly) Benchmarks
| United Therapeutics Corp | 151.40M |
| AIM ImmunoTech Inc | 3.20M |
| Perspective Therapeutics Inc | 6.08M |
| Protalix BioTherapeutics Inc | 3.102M |
| Armata Pharmaceuticals Inc | 7.928M |